journal article·2021-08

Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy

Xiang Xiong, Jingya Zhao, Rui Su, Chunping Liu, Xing Guo, Shaobing Zhou

Nano Today· Volume 39
Publisher page

Abstract

Abstract Immunogenic cell death (ICD) of tumor cells can produce plentiful tumor-associated antigens (TAAs) and release damage-associated molecules to communicate a danger situation. Damage-associated molecular patterns induce the antigen presentation ability of dendritic cells (DCs), activating the immune response cells and generating anti-tumor immune response. However, the immunosuppressive microenvironment in tumor tissues leads to a small amount of DCs in tumor tissues and suppresses their function, limiting the activation of immune response. Herein we report a tumor immunotherapy strategy by the combination of intravenous injection of doxorubicin (DOX)-loaded PLGA nanoparticles (DOX@P) coating with cell membranes (DOX@PM) and intratumoral injection of the lymphotactin (XCL-1)-loaded sodium alginate. The biomimetic nanocarriers facilitate the DOX targeted delivery to tumor, inducing a high degree of ICD. XCL-1 chemokines released from the in situ formed alginate hydrogel recruit a large amount of XCR-1+ DCs into the tumor tissue, which can capture more TAAs and mediate more cross-presentation of antigens to activate CD4+ and CD8+ T cells. As a result, in vivo antitumor experiments indicate that the double enhancement of immunogenic cell death and antigen presentation with this immunotherapy strategy improve the tumor therapy efficacy. This work provides a new strategy for enhanced tumor immunotherapy.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (62)

Show source-provided references
1. Cancer immunotherapy10.1126/science.342.6165.1432 ↗
2. Targeting immunosuppressive adenosine in cancer10.1038/nrc.2017.86 ↗
3. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival10.1016/j.ccr.2014.04.005 ↗
4. Turning foes to friends: targeting cancer-associated fibroblasts10.1038/s41573-018-0004-1 ↗
5. Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression10.1158/0008-5472.CAN-11-2772 ↗
6. Sheddable prodrug vesicles combating adaptive immune resistance for improved photodynamic immunotherapy of cancer10.1021/acs.nanolett.9b04012 ↗
7. Binary cooperative prodrug nanoparticles improve immunotherapy by synergistically modulating immune tumor microenvironment10.1002/adma.201803001 ↗
8. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
9. Artificially reprogrammed macrophages as tumor‐tropic immunosuppression‐resistant biologics to realize therapeutics production and immune activation
10. A biomimetic polymer magnetic nanocarrier polarizing tumor‐associated macrophages for potentiating immunotherapy10.1002/smll.202003543 ↗
11. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy10.1002/adma.201803322 ↗
12. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment10.1039/C6CS00592F ↗
13. Cancer immunotherapy comes of age10.1038/nature10673 ↗
14. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy10.1038/nrc3670 ↗
15. Adoptive cell transfer: a clinical path to effective cancer immunotherapy10.1038/nrc2355 ↗
16. Cancer immunotherapy using checkpoint blockade10.1126/science.aar4060 ↗
17. The human vaccines project: a roadmap for cancer vaccine development10.1126/scitranslmed.aaf0685 ↗
18. Advanced biomaterials for cancer immunotherapy10.1038/s41401-020-0372-z ↗
19. Towards personalized, tumour-specific, therapeutic vaccines for cancer10.1038/nri.2017.131 ↗
20. Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity10.1002/adma.201703969 ↗
21. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery10.1021/nl500618u ↗
22. Cancer immunotherapy–revisited10.1038/nrd3500 ↗
23. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy10.1021/acsnano.8b07371 ↗
24. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
25. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme
26. Bacteria‐based cancer immunotherapy
27. Immunogenic cell death in cancer and infectious disease10.1038/nri.2016.107 ↗
28. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy10.1021/acs.nanolett.1c00209 ↗
29. Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy10.1002/anie.201804882 ↗
30. Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy10.1016/j.biomaterials.2020.119964 ↗
31. A polymer multicellular nanoengager for synergistic NIR-II photothermal immunotherapy
32. Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer10.1038/s41467-021-21047-0 ↗
33. A multifunctional biomimetic nanoplatform for relieving hypoxia to enhance chemotherapy and inhibit the PD‐1/PD‐L1 axis10.1002/smll.201801120 ↗
34. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer10.1021/acsnano.7b00715 ↗
35. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade10.1126/science.aaf1490 ↗
36. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
37. Understanding the tumor immune microenvironment (TIME) for effective therapy10.1038/s41591-018-0014-x ↗
38. Semiconducting polymer nano-PROTACs for activatable photo-immunometabolic cancer therapy10.1038/s41467-021-23194-w ↗
39. Innate and adaptive immune cells in the tumor microenvironment10.1038/ni.2703 ↗
40. A highly active form of XCL1/lymphotactin functions as an effective adjuvant to recruit cross-presenting dendritic cells for induction of effector and memory CD8+ T cells10.3389/fimmu.2018.02775 ↗
41. Oncology meets immunology: the cancer-immunity cycle10.1016/j.immuni.2013.07.012 ↗
42. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells10.1016/j.immuni.2009.08.027 ↗
43. Turning cold into hot: firing up the tumor microenvironment10.1016/j.trecan.2020.02.022 ↗
44. Cell membrane coating nanotechnology10.1002/adma.201706759 ↗
45. Macrophage-membrane-coated nanoparticles for tumor-targeted chemotherapy10.1021/acs.nanolett.7b05263 ↗
46. Improving cancer immunotherapy by cell membrane‐camouflaged nanoparticles10.1002/adfm.202004397 ↗
47. Molecular and nanoengineering approaches towards activatable cancer immunotherapy10.1039/C9CS00773C ↗
48. Advances in the application of injectable thermosensitive hydrogel systems for cancer therapy10.1166/jbn.2020.2988 ↗
49. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response10.1158/0008-5472.CAN-12-2027 ↗
50. XCL1 and XCR1 in the immune system10.1016/j.micinf.2011.10.003 ↗
51. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression
52. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting10.1146/annurev-immunol-020711-074950 ↗
53. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses10.1038/s41551-018-0262-6 ↗
54. Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies10.1016/j.canlet.2018.08.028 ↗
55. Induction of potent CD8 T cell cytotoxicity by specific targeting of antigen to cross-presenting dendritic cells in vivo via murine or human XCR110.4049/jimmunol.1401903 ↗
56. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy10.1038/nri.2017.49 ↗
57. IL-6 in inflammation, immunity, and disease10.1101/cshperspect.a016295 ↗
58. A guide to cancer immunotherapy: from T cell basic science to clinical practice10.1038/s41577-020-0306-5 ↗
59. T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection10.1158/2326-6066.CIR-18-0277 ↗
60. The two faces of interferon-γ in cancer10.1158/1078-0432.CCR-11-0482 ↗
61. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity10.1172/JCI68395 ↗
62. Cytokines in cancer immunotherapy10.3390/cancers3043856 ↗